Skip to main content
Add Me To Your Mailing List
Organization of Regulatory and Clinical Associates
Contact Information:
Organization of Regulatory and Clinical Associates
P.O. Box 3490
Redmond, WA 98073
HomeCurrent/Future EventsChallenges of Outsourcing Gene Therapy Projects

Current/Future Events - Event View

This is the "Event Detail" view, showing all available information for this event. If the event has passed, click the "Event Report" button to read a report and view photos that were uploaded.

Challenges of Outsourcing Gene Therapy Projects

Wednesday, March 6, 2019, 8:00 AM until 10:00 AM
Bellevue Sheraton
Venue website
100 112th Ave NE
Bellevue, WA  98004

(425) 455-3330
Regular Monthly Meeting
Registration is closed

RSVP by 02/28/2019
Registration: 7:30 a.m. – 8:00 a.m. PST
Meeting: 8:00 a.m. – 10:00 a.m. PST


PARKING - Free parking available at the Bellevue Sheraton Hotel on the day of the meeting.

Credit card payments can only be accepted online prior to the meeting. If you plan on paying at the door, please note that the Registration Team can only accept CASH or CHECKS.
No Fee

TOPIC: Challenges of Outsourcing Gene Therapy Projects

The field of gene therapy is currently in a transition period. The first few therapeutic successes and approved products have led to much excitement and investment, but with associated growing pains. Venture startups expect to be able to outsource similarly to Mab projects, but outsourcing options for gene therapy are not nearly as well developed and are often over capacity. At the same time, the impact of breakthrough therapy designation may be increasing regulatory expectations, which challenges assumptions used for development plans.

SPEAKER: Barbara Thorne

SPEAKER BIOGRAPHY: Barbara Thorne has over 25 years of experience in process development of recombinant proteins, viral vectors, and vaccines, and has worked in small biotech, large pharma, and contract manufacturing organizations (CMO), and is currently an independent consultant (Thorne Bio-Consulting LLC).   Previously, she was Executive Director of Product Development at Celladon Corporation, a late-stage clinical biotechnology company developing MYDICAR (AAV1/SERCA2a) to treat heart failure, and director of Process Development at Targeted Genetics Corporation (TGC), Seattle WA where she was responsible for developing manufacturing processes for AAV and adenoviral vectors.  She has also held various scientific and process development roles at Bristol Myers Squibb, and consulted for biotechnology and contract manufacturing organizations.    She received her PhD in molecular biology from the University of Oregon.

WHO: Clinical, regulatory, quality, manufacturing and legal

This meeting includes:
- Coffee and tea
- Pastries and fresh fruit

Attendance at this meeting may be applied as 1.5 points towards RAC re-certification